FMD-15211-HQH

Electronic Supplementary Material



Fig.S1


Fig.S2

A

PE-A subset-1
78.1%

PE-A subset
8.52%

Count

PI   PE-A
Scramble

PE-A subset-1
80.1%

PE-A subset
7.87%

Count

PE-A
shRNA-22

PE-A subset-1
85.6%

PE-A subset
7.10%

Count

PE-A
shRNA-47

B

12.5%   0.7%

86.8%

PI

AnnexinV
Scramble

9.85%   0.15%

90%

shRNA-22

14.1%   0.2%

85.7%

shRNA-47

C

	24H	48H	72H
PC3	1.554	1.7625	2.089
PC3+Scramble	1.639	1.8815	2.166
PC3+shRNA-22	1.588	1.8835	2.1435
PC3+shRNA-47	1.682	1.948	2.185

Fig.S3

PC3

LNCAP

Sample1
Sample2
Sample3
Sample4
Sample5
Sample6
Sample7
Sample8
Sample9
Sample10

Fig.S4

Table S1 Clinical data of collected prostate cancer patients

Patients	Gleason scores	Age（year）	Clinical stage	Dab2 expression
1	7	77	T1	+
2	6	69	T1	+
3	7	72	T1	+
4	9	71	T2	++
5	6	66	T2	++
6	8	64	T2	++
7	6	80	T3	+++
8	9	66	T3	+++
9	7	61	T3	++
10	7	79	T3N1M1	++++
11	9	65	T4N1	++++
12	6	57	T3M1	++++